Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24454832 | 0.88 | KMT2A (0.44) | SMN1; SMN2NOS3NOS1NOS2L3MBTL3 | |
| SCHEMBL8434577 | 0.86 | HRH3 (0.41) | SMN1; SMN2NOS3NOS1NOS2HRH3 | |
| SCHEMBL684126 | 0.86 | HRH3 (0.41) | SMN1; SMN2NOS3NOS1NOS2HRH3 | |
| SCHEMBL734698 | 0.86 | HRH3 (0.41) | SMN1; SMN2NOS3NOS1NOS2HRH3 | |
| SCHEMBL13804216 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2NOS3NOS1NOS2HSD11B1 | |
| SCHEMBL10223659 | 0.81 | DRD2 (0.44) | NOS3NOS1NOS2NPY1R | |
| SCHEMBL19312034 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2NOS3NOS1NOS2HSD11B1 | |
| SCHEMBL12464449 | 0.81 | NOS3 (0.44) | SMN1; SMN2NOS3NOS1NOS2HSD11B1 | |
| SCHEMBL26872754 | 0.79 | ALOX15 (0.41) | SMN1; SMN2 | |
| SCHEMBL2392074 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2NOS3NOS1NOS2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393919-A1 | LSD1 MODULATORS | Exscientia Al Limited (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| WO-2023163527-A1 | NOVEL COMPOUND HAVING INHIBITORY ACTIVITY AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, AND USES THEREOF | 주식회사 카나프테라퓨틱스 | 2023-08-31 | — | — | WO | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-7342011-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070275951-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | MUELLER STEPHAN G | 2007-11-29 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| WO-2005012312-A1 | NOVEL CYANO THIAZOLIDES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | PDE4B, PDE4A, PDE3B | SMN1; SMN2 3728/4885NOS3 39/4885NOS1 134/4885 |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | SMN1; SMN2 2264/4885NOS3 4542/4885NOS1 4331/4885 |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SMN1; SMN2 1984/4885NOS3 3802/4885NOS1 3261/4885 |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | SMN1; SMN2 3149/4885NOS3 3393/4885NOS1 3029/4885 |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ABCB11, FPR1, C5 | SMN1; SMN2 3910/4885NOS3 1193/4885NOS1 766/4885 |
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | PDE4A, PDE4B, PDE3B | SMN1; SMN2 3552/4885NOS3 91/4885NOS1 151/4885 |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | SMN1; SMN2 3216/4885NOS3 3231/4885NOS1 3032/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | SMN1; SMN2 2106/4885NOS3 3769/4885NOS1 4270/4885 |
| US-20070275951-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | SMN1; SMN2 3886/4885NOS3 1011/4885NOS1 924/4885 |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | QDPR, NQO2, CYP3A4 | SMN1; SMN2 3095/4885NOS3 2447/4885NOS1 2880/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | SMN1; SMN2 1176/4885NOS3 3032/4885NOS1 2469/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | SMN1; SMN2 3902/4885NOS3 3970/4885NOS1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.